$YORW

YORK WATER CO (YORW): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

YORK WATER CO (YORW) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At its regularly scheduled meeting on August 17, 2026, the Board of Directors (the “Board”) of The York Water Company (the

Original reporting
Published Aug 18, 2026, 6:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 6:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$YORW
Neutral
medium confidence
Mentioned
$YORW
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$YORWNeutralLow
01

Why it matters

The newest disclosed fact is the appointment of an independent director with prior utility leadership experience, effective September 1, 2026, plus assignment to the Executive Committee. The filing states there is no arrangement requiring Item 404(a) disclosure and no reportable transaction with the director.

02

Market read

This is a governance update without disclosed financial or operational changes, so trading impact should be limited.

03

What to watch

No details are given on compensation changes, committee roles beyond Executive Committee assignment, or any strategic mandate, limiting the ability to trade on fundamentals.

Relevance 6/10Novelty 3/10Timing: effective September 1, 2026 director appointment disclosed in today’s 8-K filing

Background

The company filed an SEC Form 8-K (Item 5.02) reporting board and officer-related changes.

Company-level read

Ticker impact

$YORWNeutralMedium confidence
Context

York Water Company appointed David M. Velazquez as a new independent director effective September 1, 2026, per its Aug. 17, 2026 8-K.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to governance sentiment rather than earnings power.

Evidence & confidence

The filing discloses a director appointment and committee assignment, with no disclosed related-party transaction or immediate operational/financial guidance changes.

Market effects

Minimal. Director appointment does not signal a sector-wide regulatory or operational shift in the water utility space.

Minimal. No geographic or rate-case specifics are provided in the filing.

None. This is a company-specific governance update.

Counterpoint

The appointment could be interpreted as positioning for future regulatory or cybersecurity initiatives given Velazquez’s utility and technology background, even though the filing provides no explicit plan.

Key entities

  • The York Water Company

    Subject of the 8-K; appointed a new independent director effective September 1, 2026.

  • David M. Velazquez

    New independent director; previously President and CEO of PECO Energy, and prior senior roles at Exelon and Pepco Holdings.

Related articles

$YORWLow

THE YORK WATER COMPANY REPORTS 2nd QUARTER AND SIX MONTHS EARNINGS

YORK WATER CO (YORW) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 NEWS RELEASE Contact Information: JT Hand, President & CEO jth@yorkwater.com -OR- Matthew E. Poff, Chief Financial Officer matthewp@yorkwater.com 717-845-3601 130 East Market Street York, PA 17401 FOR IMMEDIATE RELEASE THE YORK WATER COMPANY REPORTS 2 nd QUARTER AND

$XFORMedAI 8/10

X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures

X4 Pharmaceuticals (XFOR) secured up to $150M in debt financing from K2 HealthVentures, refinancing existing debt and providing additional capital. The initial $80M tranche was used to repay $75M in outstanding debt. The new agreement offers extended repayment terms and supports clinical development, including the potential commercial launch of mavorixafor for chronic neutropenia.

$AVOMed

Mission Produce unveils five-year targets, $100M buyback, aims to double sales and triple EBITDA by 2035

Mission Produce announced a five-year plan with mid-single-digit organic sales growth, 300bps margin expansion, and 2035 targets to double sales to $4B and triple Adjusted EBITDA to $450M. The company reaffirmed fiscal 2H26 Adjusted EBITDA outlook of $84–88M and Q426 Adjusted EBITDA of $52–55M. It also launched a $100M share repurchase program, with 290,994 shares repurchased at an average price of $12.94.